Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAYLA M BERGMANN

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1730143645
CMS profile
214770
Location
BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$32,786.96

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $15,504.45 9
GENZYME CORPORATION $6,660.15 2
SOBI, INC $5,954.30 7
Takeda Pharmaceuticals U.S.A., Inc. $3,360.66 3
Bayer Healthcare Pharmaceuticals Inc. $1,292.14 2
Adaptive Biotechnologies Corporation $15.26 1

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAYLA M BERGMANN

NPI 1730143645 · CMS profile ID 214770

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730143645?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730143645?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730143645?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1730143645?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $32,786.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $11,953.7509/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1188208661 CMS
Novo Nordisk Inc $377.4809/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188302703 CMS
Novo Nordisk Inc $964.0409/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1188731223 CMS
Novo Nordisk Inc $74.9009/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1188785583 CMS
Novo Nordisk Inc $655.0009/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1188860755 CMS
Novo Nordisk Inc $511.9809/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189160846 CMS
Novo Nordisk Inc $387.6109/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189168339 CMS
Novo Nordisk Inc $22.9409/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188470081 CMS
Bayer Healthcare Pharmaceuticals Inc. $38.8906/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225465421 CMS
Bayer Healthcare Pharmaceuticals Inc. $1,253.2506/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1225465423 CMS
GENZYME CORPORATION $6,622.0006/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1233693438 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,212.0006/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223786895 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.4906/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223923275 CMS
Takeda Pharmaceuticals U.S.A., Inc. $118.1706/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223941052 CMS
SOBI, INC $4,608.0004/10/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1240270947 CMS
SOBI, INC $6.7704/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240270964 CMS
SOBI, INC $259.1604/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240270967 CMS
Adaptive Biotechnologies Corporation $15.2603/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254935180 CMS
SOBI, INC $291.4103/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240270943 CMS
SOBI, INC $523.9603/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240270951 CMS
SOBI, INC $115.0003/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240270959 CMS
SOBI, INC $150.0003/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240270955 CMS
GENZYME CORPORATION $38.1503/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233693370 CMS
Novo Nordisk Inc $556.7501/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189161846 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,400.59 36
PY2020 $17,392.19 22
PY2021 $28,307.86 31
PY2022 $56,578.29 50
PY2023 $25,272.75 24
PY2024 $93,551.59 58
PY2025 $32,786.96 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $182,096.67 57
PY2024 Recipient $330.00 1
PY2024 Principal investigator $123,216.25 29
PY2023 Recipient $7,690.97 4
PY2023 Principal investigator $204,898.80 60
PY2022 Recipient $2,500.00 1
PY2022 Principal investigator $196,214.82 57
PY2021 Principal investigator $297,011.90 78
PY2020 Principal investigator $507,163.73 79
PY2019 Recipient $14,782.04 33
PY2019 Principal investigator $370,237.09 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $2,109.66 12/31/2020 Non-covered Recipient Entity
Medical University Of South Carolina Cystic Fibrosis Program
HESTIA3 Efficacy and Safety of Ticagrelor in Ped No dispute reported 06/30/2026 736736487
Principal investigator 1 Novo Nordisk AS $3,498.30 12/22/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343133
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,475.00 12/18/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737094935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,250.00 12/18/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737094937
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 12/18/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737094939
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 12/18/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737094941
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,482.00 12/18/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737094943
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $845.00 12/18/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737094945
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $757.00 12/18/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737094947
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 12/18/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737094949
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $455.00 12/18/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737094951
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,402.00 12/17/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 737094867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,475.00 12/01/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 737093583
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,757.00 12/01/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 737093585
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,250.00 12/01/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 737093587
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 12/01/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 737093589
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,482.00 12/01/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 737093591
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $845.00 12/01/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 737093593
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $455.00 12/01/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 737093595
Principal investigator 1 Novo Nordisk AS $1,200.00 11/24/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7415-4322 No dispute reported 06/30/2026 742343129
Principal investigator 1 Novo Nordisk AS $1,000.00 11/24/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7415-4322 No dispute reported 06/30/2026 742343131
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,402.00 11/02/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737091881
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,402.00 10/22/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 737090593
Principal investigator 1 Global Blood Therapeutics, Inc. $14,414.00 09/23/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-032 No dispute reported 06/30/2026 742102879
Principal investigator 1 Global Blood Therapeutics, Inc. $9,049.00 09/23/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-032 No dispute reported 06/30/2026 742102881
Principal investigator 1 Global Blood Therapeutics, Inc. $4,402.00 09/23/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-032 No dispute reported 06/30/2026 742102883
Principal investigator 1 Global Blood Therapeutics, Inc. $3,250.00 09/23/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-032 No dispute reported 06/30/2026 742102885
Principal investigator 1 Global Blood Therapeutics, Inc. $2,130.00 09/23/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-032 No dispute reported 06/30/2026 742102887
Principal investigator 1 Global Blood Therapeutics, Inc. $1,482.00 09/23/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-032 No dispute reported 06/30/2026 742102889
Principal investigator 1 Global Blood Therapeutics, Inc. $1,235.00 09/23/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-032 No dispute reported 06/30/2026 742102891
Principal investigator 1 Global Blood Therapeutics, Inc. $845.00 09/23/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-032 No dispute reported 06/30/2026 742102893
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,750.00 09/15/2020 Covered Recipient Teaching Hospital
Medical University Of South Carolina
PK PD SD Study in Pediatric Patients No dispute reported 06/30/2026 736757079
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,729.70 09/10/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 737087761
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $506.00 09/10/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 737087763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $404.80 09/10/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 737087765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $749.00 08/12/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 737086479
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,900.00 08/06/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 737086235
Principal investigator 1 Novo Nordisk AS $2,138.76 07/28/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343127
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 07/23/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 737085605
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,200.00 07/22/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 737085567
Principal investigator 1 Global Blood Therapeutics, Inc. $2,264.00 07/01/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-032 No dispute reported 06/30/2026 742102873
Principal investigator 1 Global Blood Therapeutics, Inc. $2,000.00 07/01/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-032 No dispute reported 06/30/2026 742102875
Principal investigator 1 Global Blood Therapeutics, Inc. $6,857.60 06/25/2020 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GBT440-031 No dispute reported 06/30/2026 742102871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $506.00 06/24/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 737084081
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $404.80 06/24/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
GLOBAL EPIDEMIOLOGIC STUDY OF PREEXISTING IMMUNITY TO AAV IN ADULTS WITH SEVERE HEMOPHILIA No dispute reported 06/30/2026 737084083
Principal investigator 1 PFIZER INC. $830.44 06/04/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT No dispute reported 06/30/2026 742959343
Principal investigator 1 PFIZER INC. $4,092.40 05/14/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 742952261
Principal investigator 1 Novartis Pharmaceuticals Corporation $75,321.36 05/13/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PROSPECTIVE PHASE II, OPEN-LABEL, SINGLE-ARM, MULTICENTER, STUDY TO ASSESS EFFICACY AND SAFETY OF SEG101 (CRIZANLIZUMAB), IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM No dispute reported 06/30/2026 721493249
Principal investigator 1 PFIZER INC. $250.00 04/30/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 742968803
Principal investigator 1 Novo Nordisk AS $2,916.81 04/23/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343087
Principal investigator 1 PFIZER INC. $4,250.00 04/13/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 742968745
Principal investigator 1 PFIZER INC. $3,405.50 04/13/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 742968797
Principal investigator 1 PFIZER INC. $3,738.00 04/13/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 742968799
Principal investigator 1 Genentech, Inc. $14,528.00 03/30/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINAA
EMICIZUMAB MINOR SURGERY No dispute reported 06/30/2026 743078453
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343093
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343095
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343097
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343099
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343101
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343103
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343105
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343107
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343109
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343111
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343113
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343115
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343117
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343119
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343121
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343123
Principal investigator 1 Novo Nordisk AS $13.00 03/27/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343125
Principal investigator 1 Novo Nordisk AS $1,847.43 03/26/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343085
Principal investigator 1 AstraZeneca UK Limited $24,307.05 03/02/2020 Non-covered Recipient Entity
Medical University Of South Carolina Cystic Fibrosis Program
HESTIA3 Efficacy and Safety of Ticagrelor in Ped No dispute reported 06/30/2026 736748021
Principal investigator 1 Novo Nordisk AS $1,069.38 02/25/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 742343083
Principal investigator 1 Novartis Pharmaceuticals Corporation $210,617.74 02/13/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN SEQUENTIAL DESCENDING AGE GROUPS OF PEDIATRIC SICKLE CELL DISEASE PATIENTS WITH VASO OCCLUSIVE CRIS No dispute reported 06/30/2026 721493241
Principal investigator 1 Novo Nordisk AS $2,500.00 01/28/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7415-4322 No dispute reported 06/30/2026 742343089
Principal investigator 1 Novo Nordisk AS $1,500.00 01/28/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7415-4322 No dispute reported 06/30/2026 742343091
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $594.00 01/07/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 737067397
Principal investigator 1 PFIZER INC. $1,115.00 01/02/2020 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF VASOOCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 742968742